Compare BTG & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTG | STVN |
|---|---|---|
| Founded | 2006 | 1949 |
| Country | Canada | Italy |
| Employees | N/A | N/A |
| Industry | Precious Metals | Containers/Packaging |
| Sector | Basic Materials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 5.7B |
| IPO Year | 2007 | 2021 |
| Metric | BTG | STVN |
|---|---|---|
| Price | $5.11 | $19.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 14 |
| Target Price | $6.45 | ★ $24.47 |
| AVG Volume (30 Days) | ★ 17.7M | 311.0K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.60% | 0.32% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.66 | $7.05 |
| Revenue Next Year | $18.24 | $9.23 |
| P/E Ratio | $34.75 | ★ $27.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.57 | $12.89 |
| 52 Week High | $6.29 | $27.99 |
| Indicator | BTG | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 45.93 | 33.12 |
| Support Level | $5.08 | $18.87 |
| Resistance Level | $5.68 | $19.70 |
| Average True Range (ATR) | 0.18 | 0.85 |
| MACD | -0.05 | -0.26 |
| Stochastic Oscillator | 22.78 | 10.46 |
B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.